These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1584 related articles for article (PubMed ID: 27663795)

  • 21. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis.
    Tsai YF; Huang CC; Lin YS; Hsu CY; Huang CP; Liu CY; Chiu JH; Tseng LM
    Cancer Immunol Immunother; 2021 Aug; 70(8):2339-2351. PubMed ID: 33512556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
    Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer.
    Black JL; Harrell JC; Leisner TM; Fellmeth MJ; George SD; Reinhold D; Baker NM; Jones CD; Der CJ; Perou CM; Parise LV
    Breast Cancer Res Treat; 2015 Jul; 152(2):337-46. PubMed ID: 26105795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells.
    Belguise K; Milord S; Galtier F; Moquet-Torcy G; Piechaczyk M; Chalbos D
    Oncogene; 2012 Nov; 31(47):4889-97. PubMed ID: 22286759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alcohol promotes migration and invasion of triple-negative breast cancer cells through activation of p38 MAPK and JNK.
    Zhao M; Howard EW; Parris AB; Guo Z; Zhao Q; Yang X
    Mol Carcinog; 2017 Mar; 56(3):849-862. PubMed ID: 27533114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA‑27a promotes tumorigenesis via targeting AKT in triple negative breast cancer.
    Wu J; Sun Z; Sun H; Li Y
    Mol Med Rep; 2018 Jan; 17(1):562-570. PubMed ID: 29115608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.
    González-González A; Muñoz-Muela E; Marchal JA; Cara FE; Molina MP; Cruz-Lozano M; Jiménez G; Verma A; Ramírez A; Qian W; Chen W; Kozielski AJ; Elemento O; Martín-Salvago MD; Luque RJ; Rosa-Garrido C; Landeira D; Quintana-Romero M; Rosato RR; García MA; Ramirez-Tortosa CL; Kim H; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Lorente JA; Sánchez-Rovira P; Chang JC; Granados-Principal S
    Clin Cancer Res; 2018 Nov; 24(22):5697-5709. PubMed ID: 30012564
    [No Abstract]   [Full Text] [Related]  

  • 30. RSK-mediated down-regulation of PDCD4 is required for proliferation, survival, and migration in a model of triple-negative breast cancer.
    Cuesta R; Holz MK
    Oncotarget; 2016 May; 7(19):27567-83. PubMed ID: 27028868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
    Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
    Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
    J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
    Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
    Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crosstalk between miR-203 and PKCθ regulates breast cancer stem cell markers.
    Salem S; Mosaad R
    Ann Hum Genet; 2021 May; 85(3-4):105-114. PubMed ID: 33576006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
    Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
    J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
    Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
    BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
    Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
    Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An indispensable role of TAZ in anoikis resistance promoted by OTUB1 deubiquitinating enzyme in basal-like triple-negative breast cancer cells.
    Nakagawa H; Higurashi M; Ishikawa F; Mori K; Shibanuma M
    Biochem Biophys Res Commun; 2023 Mar; 649():1-9. PubMed ID: 36738577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
    Wu X; Zahari MS; Renuse S; Kelkar DS; Barbhuiya MA; Rojas PL; Stearns V; Gabrielson E; Malla P; Sukumar S; Mahajan NP; Pandey A
    Oncotarget; 2017 Jan; 8(2):2971-2983. PubMed ID: 27902967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 80.